Pharming Group N.V.
NASDAQ:PHARBiotechnology
+$0.28 today
- Market cap
- $882.43M
- Beta
- 0.10
- P/E (TTM)
- 77.0
- EPS (TTM)
- $0.02
Volume 0.01M
Average 0.01M
PHAR Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Pharming Group N.V.NASDAQ: PHAR
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures declines year over year
Q1 FY2026 capital expenditures of $238.86K (cash outflow) fell 17.1% year over year, ahead of the -29.8% change in trailing-twelve-month capital expenditures. Sequentially, it fell 11.3% from the prior quarter. Over 3 fiscal years it compounded at -27.6% a year.
Context
- Capital expenditures amounted to 0.2% of revenue in FY2025, unchanged from a year earlier.
- Capital expenditures grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -17.1% holds above the trailing-twelve-month pace of -29.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (751.09K) USD
- Year-over-year change
- +8.9%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (751.09K) | +8.9% |
| FY2024 | 2024-12-31 | (824.25K) | +43.7% |
| FY2023 | 2023-12-31 | (1.46M) | +25.9% |
| FY2022 | 2022-12-31 | (1.98M) | +89.6% |
| FY2021 | 2021-12-31 | (18.95M) | — |
Capital Expenditures vs competitors
How PHAR compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -29.8% is the 6th highest of 9, against a peer median of +17.1%.
- Capital expenditures amounts to 0.2% of revenue for PHAR, versus a peer median of 7.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $78.07B USD | +88701.7% | -5.2% | 7.6% | |
| LTM Sep 2026 | $71.85M USD | +29.1% | +36.8% | 7.5% | |
| LTM Jun 2026 | $2.76M USD | +161.2% | +22.2% | 0.3% | |
| LTM Mar 2026 | €955.79K EUR | +5.0% | +11.4% | 7.1% | |
| LTM Mar 2026 | $871K USD | +153.9% | -44.7% | 2.7% | |
| LTM Mar 2026 | $704.82K USD | -29.8% | -27.6% | 0.2% | |
| LTM Mar 2026 | $473K USD | -88.2% | -53.7% | 0.7% | |
| LTM Mar 2026 | $169K USD | -96.0% | -62.9% | — | |
| LTM Mar 2026 | $106K USD | — | -53.4% | 11.5% | |
| LTM Sep 2026 | €81.4K EUR | -74.9% | +9.8% | — | |
| Peer median (excluding PHAR) | — | +17.1% | -5.2% | 7.1% | |
Competitors are the stored peer set for PHAR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 26.16M | 14.99M | (12.01M) | (8.79M) | 2.86M |
| Depreciation & Amortization | 22.23M | 13.19M | 15.93M | 16.64M | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.27M | 6.39M | 9.25M | 11.65M | 0 |
| Change in Working Capital | (5.62M) | (387K) | (16.96M) | (10.43M) | 14.4M |
| Accounts Receivables | 6.71M | 2.36M | (18.54M) | (7.02M) | (3.36M) |
| Inventory | (6.98M) | (15.02M) | (14.43M) | (520.85K) | (1.29M) |
| Accounts Payables | 0 | 0 | 0 | 0 | 17.87M |
| Other Working Capital | (5.36M) | 12.27M | 16.01M | (2.88M) | 1.19M |
| Other Non-Cash Items | (10.14M) | (11.72M) | (13.51M) | (10.92M) | 32.8M |
| Operating Cash Flow | 42.9M | 22.46M | (17.3M) | (1.86M) | 50.07M |
| Capital Expenditures | (18.95M) | (1.98M) | (1.46M) | (824.25K) | (751.09K) |
| Acquisitions (Net) | 0 | 7.3M | 0 | 0 | (65.53M) |
| Purchases of Investments | (5.2M) | 0 | (382.01M) | (294.4M) | 0 |
| Sales of Investments | 0 | 0 | 232.81M | 327.97M | 0 |
| Other Investing Activities | 0 | 0 | 21.28M | 0 | 84.72M |
| Investing Cash Flow | (24.15M) | 5.32M | (129.39M) | 32.74M | 18.43M |
| Debt Repayment | (3.65M) | (3.31M) | (4.04M) | (35.61M) | 0 |
| Common Stock Issued | 5.35M | 2.28M | 0 | 0 | 19.87M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (33.39M) | (3.95M) | 3M | (19.67K) | (5.39M) |
| Financing Cash Flow | (31.68M) | (4.98M) | (1.04M) | (35.63M) | 14.48M |
| Effect of Forex Changes | (2.07M) | (7.38M) | 2.13M | (2.29M) | 8.12M |
| Net Change in Cash | (15M) | 15.42M | (145.6M) | (7.04M) | 91.09M |
| Free Cash Flow | 23.95M | 20.48M | (18.77M) | (2.68M) | 49.31M |
Pharming Group N.V.
NASDAQ:PHAR
Intrinsic Alpha fair value
Locked
Current Price
$12.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.